| Literature DB >> 32702630 |
M Bonomi1, P Bhateja2, M Issa2, B Klamer3, X Pan3, A Blakaj4, V Karivedu2, L Mousa2, D Mitchell5, M Gamez5, S Kang6, Nolan B Seim6, M Old6, R Carrau6, J Rocco6, D Blakaj5.
Abstract
BACKGROUND: ICIs have expanded treatment options for HNSCC. A minority of the patients respond to these expensive treatments. PATIENTS AND METHODS: This is a single institutional retrospective review on 121 unresectable or metastatic HNSCC patients treated with ICIs. We predicted that inflammatory markers available through routine blood work, in addition to clinical characteristics may divide patients into groups more or less likely to respond to these agents. Here we develop and internally validate our nomogram to predict survival in patients treated with ICIs.Entities:
Keywords: Head and neck cancer; Immunotherapy; Metastatic; PD-1 inhibitors; Predictors; Response
Mesh：
Substances：
Year: 2020 PMID： 32702630 DOI： 10.1016/j.oraloncology.2020.104900
Source DB: PubMed Journal: Oral Oncol ISSN： 1368-8375 Impact factor: 5.337